Coya Therapeutics (NASDAQ: COYA)
The company's diverse pipeline of Treg-modulating candidates seeks to restore immune balance by targeting inflammation, a common and critical factor in the progression of numerous neurodegenerative diseases (NDDs) and autoimmune diseases. Coya aims to treat 1.7 million patients across the U.S., with a total addressable market exceeding $7 billion. Moreover, Coya recently reported encouraging results from its proof-of-concept study in ALS patients. COYA 302 effectively slowed disease progression, as demonstrated by a lack of decline at 24 weeks and minimal decline at 48 weeks after initiation of treatment in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores compared to score values at baseline. A higher ALSFRS-R score represents better functional status in ALS patients. The positive clinical results were consistent with the increased Treg function observed over the treatment period.
Quantum Research Group, LLC is a New York City-based sponsored equity research and distribution company.
The company focuses on emerging growth public companies that are seeking detailed equity analysis and extensive distribution aimed at the investment community.
Our distribution partners include dozens of the leading financial platforms, including Thomson Reuters, Standard & Poor's Capital IQ, Bloomberg, Zacks, NASDAQ, Yahoo! Finance, and NYSE Connect.
Our reports reach over 20 channels, with our top five platforms reaching over 818,000 readers from both the buy-side and sell-side.
Quantum has a strong proven track record in the fields of Biotechnology/Pharma, Technology, Telecommunication, Media/News, Transportation, Insurance and Fintech.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.